Cure Parkinson’s is an international funder of both preclinical and clinical research.

Before an experimental treatment can be tested in humans, there needs to be evidence that it works in laboratory models of Parkinson’s; this information helps provide a case for support in taking the treatment forward into clinical testing in people.

In addition to our extensive clinical trials programme, we also fund preclinical research to determine if a treatment has potential as a Parkinson’s therapy.

We are selective in the nature of preclinical research we fund; the studies must be focussed on changing the course of Parkinson’s (disease modifying) and must be within 5 years of reaching the clinic.

Preclinical research supported by us includes screening clinically approved drugs that inhibit particular Parkinson’s-associated proteins. We also fund studies investigating novel agents (that are being clinically developed for other medical conditions) in the laboratory to determine if they should be repurposed for Parkinson’s.

 


Latest updates

New mRNA activators for Parkinson’s

Research evidence has suggested that in Parkinson’s there is some disruption to a process involved in protein production within cells. This process is known...

The lonafarnib pre-clinical trial

This research led by Professor Joe Mazzulli, will, it is hoped, give us a better understanding of how lonafarnib can reduce the build-up of...

Diabetes dual agonist drugs for Parkinson’s

Glucagon-like peptide 1 receptor (or GLP-1R) agonists are recognised as a frontline treatment for diabetes. Researchers have recently been developing the next generation of...

Neurotrophic Factor GDF5 – an alternative to GDNF?

Neurotrophic factors are small protein that are naturally produced in the brain to help nurture and protect nerve cells (neurons). Cure Parkinson's is...

Nerve growth factors and Parkinson’s

Nerve growth or neurotrophic factors such as CDNF and GDNF are proteins that support neurons and encourage their growth and survival during development. There...